New IVIG therapy aims to shield patients with rare immune disorders
NCT ID NCT06954441
First seen Jan 20, 2026 · Last updated May 15, 2026 · Updated 16 times
Summary
This study tests a medicine called V-IMMUNE® in about 50 people aged 2 and older who have a weak immune system (primary immunodeficiency). Participants will receive V-IMMUNE® infusions every three weeks for a year. The goal is to see if it safely reduces serious infections and improves quality of life.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY IMMUNODEFICIENCIES (PID) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
IMIP Centro de Pesquisa
RECRUITINGRecife, Pernanbuco, 50070-902, Brazil
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.